Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 11/20 | 0.60 |
| ▸ | TUBB | P07437 | 11/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 11/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 11/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 11/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 11/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 11/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 11/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 11/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 11/20 | 0.60 |
| ▸ | TUBA1A | Q71U36 | 11/20 | 0.60 |
| ▸ | TUBA1C | Q9BQE3 | 11/20 | 0.60 |
| ▸ | TUBB6 | Q9BUF5 | 11/20 | 0.60 |
| ▸ | TUBB2B | Q9BVA1 | 11/20 | 0.60 |
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 0.60 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401551 | 0.94 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2133275 | 0.92 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1401504 | 0.92 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1401526 | 0.91 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13622251 | 0.88 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1401575 | 0.87 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13622179 | 0.86 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13622165 | 0.86 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13622159 | 0.86 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13622155 | 0.86 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646608-B1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2011-03-02 | — | — | EP | claimed |
| EP-1646608-B1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2011-03-02 | — | — | EP | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | VEGFA, TUBB3, TUBA3C | TUBB4A 10/4885TUBB 7/4885TUBA3C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.